Joshua DE - Search Results

1

Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.

Brown RD, Joshua DE, Ioannidis RA, Kronenberg H. Brown RD, et al. Among authors: joshua de. Aust N Z J Med. 1989 Jun;19(3):226-32. doi: 10.1111/j.1445-5994.1989.tb00251.x. Aust N Z J Med. 1989. PMID: 2528340

2

The oncoprotein phenotype of plasma cells from patients with multiple myeloma.

Brown RD, Pope B, Luo XF, Gibson J, Joshua D. Brown RD, et al. Leuk Lymphoma. 1994 Dec;16(1-2):147-56. doi: 10.3109/10428199409114152. Leuk Lymphoma. 1994. PMID: 7696921

3

C-reactive protein (CRP) levels do not reflect disease status in patients with multiple myeloma.

Brown RD, Snowdon L, Uhr E, Gibson J, Joshua D. Brown RD, et al. Leuk Lymphoma. 1993 Apr;9(6):509-12. doi: 10.3109/10428199309145758. Leuk Lymphoma. 1993. PMID: 8339052

4

Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression.

Wearne AJ, Joshua DE, Brown RD, Kronenberg H. Wearne AJ, et al. Among authors: joshua de. Br J Haematol. 1987 Sep;67(1):39-44. doi: 10.1111/j.1365-2141.1987.tb02293.x. Br J Haematol. 1987. PMID: 2959309

5

Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes.

Joshua DE, Ioannidis R, Brown R, Francis SE, Gibson J, Kronenberg H. Joshua DE, et al. Am J Hematol. 1988 Sep;29(1):5-11. doi: 10.1002/ajh.2830290103. Am J Hematol. 1988. PMID: 3052044

6

Monitoring myeloma: light chain isotype suppression. A new parameter.

Wearne A, Joshua DE, Kronenberg H. Wearne A, et al. Among authors: joshua de. Aust N Z J Med. 1985 Oct;15(5):629-33. Aust N Z J Med. 1985. PMID: 3937514

7

Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.

Joshua DE, Brown RD, Gibson J. Joshua DE, et al. Leuk Lymphoma. 1994 Nov;15(5-6):375-81. doi: 10.3109/10428199409049739. Leuk Lymphoma. 1994. PMID: 7873994 Review.

8

Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial.

Brown RD, Joshua DE, Nelson M, Gibson J, Dunn J, MacLennan IC. Brown RD, et al. Among authors: joshua de. Br J Haematol. 1993 Jun;84(2):238-41. doi: 10.1111/j.1365-2141.1993.tb03058.x. Br J Haematol. 1993. PMID: 8398824 Clinical Trial.

9

Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma.

Nelson M, Brown RD, Gibson J, Joshua DE. Nelson M, et al. Among authors: joshua de. Br J Haematol. 1992 Jun;81(2):223-30. doi: 10.1111/j.1365-2141.1992.tb08211.x. Br J Haematol. 1992. PMID: 1643019

10

Multiple myeloma: evidence that light chains play an immunoregulatory role in B-cell regulation.

Ioannidis RA, Joshua DE, Warburton PT, Francis SE, Brown RD, Gibson J, Kronenberg H. Ioannidis RA, et al. Among authors: joshua de. Hematol Pathol. 1989;3(4):169-75. Hematol Pathol. 1989. PMID: 2516854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

174 results

Search Page

Filters